Tejal Somvanshi
In a world-first medical achievement, an Australian man in his 40s has made history by surviving 100 days with an artificial titanium heart before receiving a donor transplant. This milestone marks a significant advancement in heart failure treatment and offers new hope for millions suffering from this condition worldwide.
The Remarkable Journey
The patient received the BiVACOR Total Artificial Heart at St. Vincent’s Hospital Sydney in November. He became the first person ever to be discharged from hospital with this device, which kept him alive until a donor heart became available in early March.
“We’ve worked towards this moment for years and we’re enormously proud to have been the first team in Australia to carry out this procedure,” said Dr. Paul Jansz, the cardiothoracic and transplant surgeon who led the six-hour implant procedure.
How the BiVACOR Heart Works
The BiVACOR heart, developed by Australian bioengineer Dr. Daniel Timms, is the first fully implantable rotary blood pump designed to replace a human heart. Unlike traditional artificial hearts, it uses magnetic levitation technology to mimic natural blood flow.
What makes this device revolutionary is its simple design – it has just a single moving part: a levitated rotor held in place by magnets. This reduces wear and tear significantly compared to other artificial hearts.
“It was exhilarating to see decades of work come to fruition,” said Dr. Timms, who created the device after his father’s death from heart disease. “The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart.”
Similar Posts
A Personal Mission Behind the Innovation
Dr. Timms’ journey to create the BiVACOR heart was deeply personal. Inspired by his father’s death from heart failure, he combined his engineering knowledge with medical expertise to develop this groundbreaking device. His childhood experiences with water pumps on his family property influenced the mechanism’s design.
Addressing a Global Health Crisis
Heart failure affects over 23 million people worldwide, but only about 6,000 receive a donor heart each year. This stark gap highlights the critical need for alternatives like the BiVACOR heart.
The Australian government has invested AU$50 million in the Artificial Heart Frontiers Program, led by Monash University, which is developing three key devices to treat common forms of heart failure.
Expert Perspectives
Professor Chris Hayward from the Victor Chang Cardiac Research Institute called the trial a “game-changer” for heart transplants.
“The BiVACOR Total Artificial Heart ushers in a whole new ball game for heart transplants, both in Australia and internationally,” Hayward said. “Within the next decade, we will see the artificial heart becoming the alternative for patients who are unable to wait for a donor heart or when a donor heart is simply not available.”
Previous Trials and Future Outlook
The BiVACOR heart has already been tested in the United States under the Food and Drug Administration’s Early Feasibility Study, where five patients received the implant. The longest survival time before a transplant in those cases was 27 days, making the Australian trial significantly more successful.
While currently designed as a bridge to keep patients alive until a donor heart transplant becomes available, BiVACOR’s long-term ambition is for recipients to live with their device without needing a heart transplant at all.
Professor David Colquhoun from the University of Queensland and board member of the Heart Foundation noted that while this is “a great technological step forward,” there’s still “a long way to go” before the artificial heart could replace donor hearts, which typically function for more than 10 years.
The successful Australian trial represents just the beginning of what could become a transformative approach to treating heart failure, potentially saving countless lives in the years to come.
FAQ About the BiVACOR Artificial Heart
How long can someone live with the BiVACOR artificial heart?
The current record is 100 days, set by the Australian patient in this breakthrough case. However, the device is still in clinical trials, and researchers hope to extend this duration significantly in the future. The ultimate goal is for the device to serve as a permanent alternative to donor hearts.
How does the BiVACOR heart differ from other artificial hearts?
The BiVACOR heart uses magnetic levitation technology with just one moving part—a levitated rotor held in place by magnets. This design reduces wear and tear compared to traditional artificial hearts that have multiple mechanical components. It’s made of titanium and has no valves or mechanical bearings that might wear out quickly.
Is the BiVACOR heart available for patients now?
No, the BiVACOR heart is still in clinical trials and has not been approved for general use. Currently, it’s only available to patients participating in specific clinical studies, such as the FDA’s Early Feasibility Study in the US and Australia’s Artificial Heart Frontiers Program.
Who is eligible to receive this artificial heart?
Based on the current trials, the device is being tested in patients with end-stage biventricular heart failure. According to the source materials, this condition generally develops after other conditions – most commonly heart attack and coronary heart disease, but also other diseases such as diabetes – have damaged or weakened the heart so that it cannot effectively pump blood through the body.
How much does the BiVACOR artificial heart cost?
The cost information is not available in the source material. As the device is still in clinical trials, it doesn’t have a market price. However, the Australian government has invested AU$50 million in the Artificial Heart Frontiers Program that includes the BiVACOR device, indicating significant financial support for its development.
What happens if there’s a power failure with the artificial heart?
The source materials don’t provide specific information about power backup systems for the BiVACOR heart. This is an important consideration for any artificial heart technology, but the exact details of how the BiVACOR handles power management aren’t described in the provided sources.
